Bayer Diagnostics launches immunoassay system

8 September 2006

Tarrytown, N.Y., USA. Bayer HealthCare, Diagnostics Division, a member of the Bayer Group (NYSE: BAY - News), has announced the worldwide availability of its ADVIA Centaur XP Immunoassay System.

ADVIA Centaur XP system is a fully-automated, high-throughput immunoassay system enabling hospitals and reference laboratories to perform up to 240 tests per hour to keep pace with peak load times. It provides a portfolio of 65 disease state tests, and over 226 specific allergens and mixes, providing consolidation while balancing a laboratory's need for improved patient care.

The new system uses the same proven assay methodologies and reagent packs as ADVIA Centaur system and ADVIA Centaur CP system. The comprehensive menu of disease state assay groups — including cardiovascular, oncology, fertility, and infectious disease testing capabilities — currently available on the ADVIA Centaur system and ADVIA Centaur CP system are also available on ADVIA Centaur XP system.

"Our aim is to better serve our customers by offering more analytical platforms, more assays and improved connectivity and integration," said Tony Bihl, President of Bayer Diagnostics. "The addition of ADVIA Centaur XP system to Bayer's portfolio provides additional ease-of-use, automation, and expanded capabilities for significant impact on productivity in a laboratory, while improving patient care."

To top